Pfizer begins late-stage testing of Spark's hemophilia B gene therapy

Pfizer Inc. said Monday it has started late-stage clinical testing of an experimental gene therapy treatment, originally developed by Spark Therapeutics in Philadelphia, for patients with hemophilia B. The transfer of the gene therapy program to Pfizer from Spark is now complete, the companies said. Under the terms of a product license agreement signed in December 2014, Pfizer has now assumed sole responsibility for all subsequent pivotal studies, all regulatory activities, manufacturing and gl obal…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news